

# Recombinant Human Interferon- $\gamma$ (IFN- $\gamma$ )

Catalog Number PHC4031 (100  $\mu$ g), PHC4033 (1 mg)

Pub. No. MAN0003600 Rev. 3.0

## Product specifications








<b>Lot number</b>	See product label.
<b>Molecular weight</b>	16.9 kDa
<b>Purity</b>	>95% as determined by SDS PAGE analysis.
<b>Amino acid sequence</b>	QDPYVKEAEN LKKYFNAGHS DVADNGTLFL GILKNWKEES DRKIMQSQIV SFYFKLFKNF KDDQSIQKSV ETIKEDMNVK FFNSNKKKKRD DFEKLTNYSV TDLNVQRKAI HELIQVMAEL SPAAKTGKRK RSQMLFQGRR ASQ
<b>Biological activity</b>	ED <sub>50</sub> 0.5–3.0 ng/mL (specific activity: 2.0 x 10 <sup>6</sup> to 3.3 x 10 <sup>5</sup> units/mg), determined by the dose dependent cytostasis of human WiDr cells. Determine the optimal concentration for each specific application using an initial dose response assay.
<b>Formulation</b>	Purified protein in 40 mM Tris pH 7.4, carrier free.
<b>Sterility</b>	Filtered before packaging through a 0.22 micron sterile filter.
<b>Endotoxin</b>	<0.1 ng/ $\mu$ g
<b>Production</b>	Produced in <i>E. coli</i> and purified via sequential chromatography.
<b>Suggested working dilutions</b>	The optimal concentration should be determined for each specific application.
<b>Storage</b>	Store at –80°C. Upon initial thawing, we recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. The contents should then be apportioned into working aliquots and stored at –80°C. Avoid repeated freeze-thaw cycles. Further dilutions should be made in low endotoxin medium or buffered solution with FBS or tissue culture grade BSA. Recombinant human IFN- $\gamma$ should be kept as a solution in order to maintain full activity.
<b>Expiration date</b>	Expires one year from date of receipt when stored as instructed.
<b>References</b>	<p>Alderson, MR, Armitage, RJ, Tough, TW, and Ziegler, SF. (1994) Synergistic effects of IL-4 and either GM-CSF or IL-3 on the induction of CD23 expression by human monocytes: regulatory effects of IFN-<math>\alpha</math> and IFN-<math>\gamma</math>. <i>Cytokine</i> 6(4):407-413.</p> <p>Cao, HJ, Wang, HS, Zhang, Y, Lin, HY, Phipps, RP, and Smith, TJ. (1998) Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. <i>J. Biol. Chem.</i> 273 (45):29615-29625.</p> <p>Dovhey, SE, Ghosh, NS, and Wright, KL. (2000) Loss of interferon-<math>\gamma</math> inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. <i>Cancer Research</i> 60:5789-5796.</p> <p>Francisco, JA, Gawlak, SL, and Siegall, CB. (1997) Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1. <i>J. Biol. Chem.</i> 272(39):24165-24169.</p> <p>Jelinek, DF, Aagaard-Tillery, KM, Arendt, BK, Arora, T, Tschumper, RC, and Westendorf, JJ. (1997) Differential human multiple myeloma cell line responsiveness to interferon-<math>\alpha</math>. Analysis of transcription factor activation and interleukin 6 receptor expression. <i>J. Clin. Invest.</i> 99(3):447-456.</p> <p>Kahlert, H, Grage-Griebenow, E, Stuwe, HT, Cromwell, O, and Fiebig, H. (2000) T cell reactivity with allergoids: Influence of the type of APC. <i>J. Immunol.</i> 165(4):1807-1815.</p> <p>Karanikas, V, Hwang, LA, Pearson, J, Ong, CS, Apostolopoulos, V, Vaughan, H, Xing, PX, Jamieson, G, Pietersz, G, Tait, B, Broadbent, R, Thynne, G, and McKenzie, IF. (1997) Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. <i>J. Clin. Invest.</i> 100(11):2783-2792.</p> <p>Lin, HY, Martino, LJ, Wilcox, BD, Davis, FB, Gordinier, JK, and Davis, PJ. (1998) Potentiation by thyroid hormone of human IFN-<math>\gamma</math>-induced HLA-DR expression. <i>J. Immunol.</i> 161(2):843-849.</p>

<b>References</b> continued	Liuzzo, G, Vallejo, AN, Kopecky, SL, Frye, RL, Holmes, DR, Goronzy, JJ, and Weyand, CM. (2001) Molecular fingerprint of interferon-gamma signaling in unstable angina. <i>Circulation</i> 103 (11):1509-1514.
	Loparev, V, Parsons, J, Knight, J, Fanelli Panus, J, Ray, C, Buller, R, Pickup, D, and Esposito, J. (1998) A third distinct tumor necrosis factor receptor of orthopoxviruses. <i>Proc. Nat'l. Acad. Sci.</i> 95(7):3786-3791.
	Mazanet, MM, Neote, K, and Hughs, CCW. (2000) Expression of IFN-inducible T cell chemoattractant by human endothelial cells is cyclosporin A-resistant and promotes T cells adhesion: implications for cyclosporin A-resistant immune inflammation. <i>J. Immunol.</i> 164:5383-5388.
	Pfizenmaier, K, Bartsch, H, Scheurich, P, Seliger, B, Ucer, U, Vehmeyer, K, and Nagel, GA. (1985) Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth. <i>Cancer Res.</i> 45(8):3503-3509.
	Rodriguez, P, Heyman, M, Candath, C, Blaton, MA, and Bouchaud, C. (1995) Tumour necrosis factor-alpha induces morphological and functional alterations of intestinal HT29 cl.19A cell monolayers. <i>Cytokine</i> 7(5): 441-448.
	Stephens, JM, Lumpkin, SJ, and Fishman, JB. (1998) Activation of Signal Transducers and Activators of Transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon- $\gamma$ in adipocytes. <i>J. Biol. Chem.</i> 273:31408-31416.
	Subramaniam, PS, Mujtaba, MG, Paddy, MR, and Johnson, HM. (1999) The carboxyl terminus of interferon-gamma contains a functional polybasic nuclear localization sequence. <i>J. Biol. Chem.</i> 274(1):403-407.
	Subramaniam, P, Larkin III, J, Mujtaba, MG, Walter, MR, and Johnson, HM. (2000) The COOH-terminal nuclear localization sequence of interferon $\gamma$ regulates STAT1 $\alpha$ nuclear translocation at an intracellular site. <i>J. Cell Sci.</i> 113:2771-2781.
	Zhai, Y, Guo, R, Hsu, TL, Yu, GL, Ni, J, Kwon, BS, Jiang, GW, Lu, J, Tan, J, Ugustus, M, Carter, K, Rojas, L, Zhu, F, Lincoln, C, Endress, G, Xing, L, Wang, S, Oh, KO, Gentz, R, Ruben, S, Lippman, ME, Hsieh, SL, and Yang, D. (1998) LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. <i>J. Clin. Invest.</i> 102(6):1142-1151.

## Limited product warranty

Life Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies' General Terms and Conditions of Sale found on Life Technologies' website at [www.thermofisher.com/us/en/home/global/terms-and-conditions.html](http://www.thermofisher.com/us/en/home/global/terms-and-conditions.html). If you have any questions, please contact Life Technologies at [www.thermofisher.com/support](http://www.thermofisher.com/support).

## Explanation of Symbols

Symbol	Description	Symbol	Description	Symbol	Description
	Manufacturer		Catalog number		Batch code
	Use by		Temperature limitation		
	Consult instructions for use		Caution, consult accompanying documents		

**Manufacturer's address:** Life Technologies Corporation | 5781 Van Allen Way | Carlsbad, CA 92008

The information in this guide is subject to change without notice.

**DISCLAIMER:** TO THE EXTENT ALLOWED BY LAW, LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT.

**Important Licensing Information:** This product may be covered by one or more Limited Use Label Licenses. By use of this product, you accept the terms and conditions of all applicable Limited Use Label Licenses.

©2017 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.